Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
HOUSTON, March 07, 2023 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:TCRT), a clinical-stage oncology-focused cell therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.
Related news for (TCRT)
- Breaking News: MoBot’s Latest Update as of 08/22/25 10:00 AM
- PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
- PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
- MoBot alert highlights: NASDAQ: WCT, NASDAQ: TRNR, NASDAQ: TCRT, NASDAQ: CGTL, NYSE: DRIP (04/03/25 03:00 PM)
- Breaking News: MoBot’s Latest Update as of 04/03/25 01:00 PM